Screened 2026-09-16 · the tape above runs as of 21:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
Innovex International, Inc. holds its Markdown at $29.33. Consolidating, no directional conviction, held for 1 days.
As held on the ledger · 2026-09-16
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 1 days
Price at the screen
$29.33
Valuation
32.96 trailing · 15.67 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.07
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
6.25%
Below 33%
Interest-bearing debt is just 6.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
34.15%
Below 49%
Money owed to the company is 34.1% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-16 screen. The gold marker is the market price at the same screen. The price runs 13.4% above the base estimate.
Third-party analyst targets: 5 covering, consensus None. The average target sits +19% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-16 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Oil tools maker stuck in a flat cycle
Picture an oilfield supplier whose kit only earns when drillers are flush. Innovex sits right there, with revenue already slipping one percent and margins stuck at five percent. The forward multiple of 13 times looks modest until you remember this is a cyclical business where peak earnings often arrive just before the next downturn. Fair value sits level with the current price, leaving no margin of safety and no reason to step in.
The low return on equity of five percent tells the same story. Capital is not compounding, the moat is unclear, and growth has turned negative. In equipment and services tied to rig counts, a cheap multiple is usually a warning rather than a bargain, especially when the next oil-price swing can wipe out several years of thin profits.
Ethics clear the screen, yet the numbers still fail on every other test. Five analysts see upside to thirty-five dollars, but that target rests on assumptions that rarely hold through a full cycle. We pass. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
INVX trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-02Markup · changed$29.84+15.7%Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 15.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (4 analysts) rates it buy, with a mean price target of $32.
2026-08-02Distribution$25.78-12.5%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 12.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (4 analysts) rates it buy, with a mean price target of $32.
2026-07-18Distribution$29.45+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (4 analysts) rates it buy, with a mean price target of $32.
2026-07-03Distribution$29.45+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Distribution$29.45Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
